Ascent Wealth Partners LLC Buys 242 Shares of Merck & Co., Inc. (NYSE:MRK)

Ascent Wealth Partners LLC raised its stake in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 1.5% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 16,821 shares of the company’s stock after purchasing an additional 242 shares during the period. Ascent Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $2,220,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Stonegate Investment Group LLC lifted its stake in Merck & Co., Inc. by 0.3% during the 1st quarter. Stonegate Investment Group LLC now owns 24,915 shares of the company’s stock worth $3,288,000 after acquiring an additional 79 shares in the last quarter. NTV Asset Management LLC increased its stake in Merck & Co., Inc. by 0.3% during the fourth quarter. NTV Asset Management LLC now owns 26,534 shares of the company’s stock worth $2,893,000 after purchasing an additional 80 shares during the period. SRS Capital Advisors Inc. lifted its position in shares of Merck & Co., Inc. by 1.6% during the fourth quarter. SRS Capital Advisors Inc. now owns 5,037 shares of the company’s stock worth $549,000 after purchasing an additional 81 shares in the last quarter. Endowment Wealth Management Inc. boosted its stake in shares of Merck & Co., Inc. by 3.2% in the fourth quarter. Endowment Wealth Management Inc. now owns 2,637 shares of the company’s stock valued at $288,000 after purchasing an additional 81 shares during the period. Finally, Hendershot Investments Inc. grew its holdings in shares of Merck & Co., Inc. by 0.5% in the first quarter. Hendershot Investments Inc. now owns 15,756 shares of the company’s stock valued at $2,079,000 after purchasing an additional 81 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of MRK traded up $0.60 during midday trading on Friday, reaching $126.45. 6,786,713 shares of the stock were exchanged, compared to its average volume of 9,857,639. Merck & Co., Inc. has a twelve month low of $99.14 and a twelve month high of $134.63. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99. The company has a market capitalization of $320.27 billion, a price-to-earnings ratio of 140.50, a PEG ratio of 2.44 and a beta of 0.38. The business’s 50-day moving average price is $129.14 and its 200 day moving average price is $124.99.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.94 by $0.13. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The firm’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.40 earnings per share. On average, sell-side analysts expect that Merck & Co., Inc. will post 8.62 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, July 8th. Investors of record on Monday, June 17th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 2.44%. The ex-dividend date of this dividend is Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 342.22%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on MRK shares. Argus upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. Societe Generale cut Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price objective on the stock. in a research note on Monday, March 11th. Wells Fargo & Company lifted their target price on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a report on Wednesday, March 27th. Berenberg Bank upped their price target on Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price target on shares of Merck & Co., Inc. in a research report on Tuesday, June 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $133.00.

Read Our Latest Research Report on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.